Fall of the Titans: Anabolic-Androgenic Steroid Use in a Patient With a TTN Truncating Variant
Mueez Rehman1, Rawan Elkurdi1, Zachary T Wilson1
1Banner University Medical Center-Phoenix, Phoenix, Arizona, USA.
Background:
The use of nonprescription anabolic-androgenic steroids in bodybuilding is a growing concern due to the potential of severe cardiovascular side effects.
Case Presentation:
A 35-year-old man presented with acute dyspnea. Echocardiogram revealed heart failure with a reduced ejection fraction of 25%. The patient had been abusing exogenous testosterone and aromatase inhibitors over the past year but denied long-term use of these agents. Given his young age, family history, and short period of anabolic-androgenic steroid use, genetic testing was performed to evaluate for possible explanations of his severe heart failure. A pathogenic titan truncating variant was identified explaining his dilated cardiomyopathy.
Conclusions:
This case underscores the potential cardiac risks associated with anabolic-androgenic steroid use and highlights the importance of genetic testing in unexplained cardiomyopathy. Early recognition and prompt initiation of guideline-directed medical therapy can help prevent further deterioration and inform risk stratification and long-term management.
Take-Home Message:
This case highlights potential cardiovascular risk associated with supraphysiologic AAS exposure, particularly in the presence of an underlying genetic predisposition. Clinicians should consider toxin exposure and genetic predisposition in patients with unexplained cardiomyopathy.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ATP Synthase: Mechanism
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
ATP Synthase: Structure
